Among the currently used therapeutic antibodies that promote tumor cell targeting and depletion, one can cite the anti-CD20 Rituximab for B cell lymphoma [44], the anti-EGFR Cetuximab for colorectal, head and neck or lung cancers [45, 46], and the anti-KIR3DL2 Lacutamab or anti-CCR4 Mogamulizumab for cutaneous T cell lymphoma [47, 48]. This evidence concerns the gene KIR3DL2 and B-cell non-Hodgkin lymphoma.